Details of the Drug-Related molecule(s) Interaction Atlas

CGS-26303 Drug Info

Cgs-26303; Cgs 26303; 154116-31-1; CHEMBL290698; (S)-2-Biphenyl-4-yl-1-(1H-tetrazol-5-yl)ethylaminomethyl phosphonic acid; cgs26303; SCHEMBL653011; AC1L31X6; CTK4C8115; DTXSID40165541; BDBM50064106; Phosphonic acid, (((2-(1,1'-biphenyl)-4-yl-1-(1H-tetrazol-5-yl)ethyl)amino)methyl)-, (S)-; {[(S)-2-Biphenyl-4-yl-1-(2H-tetrazol-5-yl)-ethylamino]-methyl}-phosphonic acid; {[(S)-2-Biphenyl-4-yl-1-(1H-tetrazol-5-yl)-ethylamino]-methyl}-phosphonic acid; {[(R)-2-Biphenyl-4-yl-1-(1H-tetrazol-5-yl)-ethylamino]-methyl}-phosphonic ac

Cross-matching ID

PubChem CID

132968

ChEBI ID

CHEMBL290698

CAS Number

CAS 154116-31-1

TTD Drug ID

DMFZM09

General Information of Drug (ID: DMFZM09)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Neutral endopeptidase (MME)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LCZ696	DMLFX7K	Heart failure	BD10-BD13	Approved	[2]
Candoxatril	DMHJCGV	Hypertension	BA00-BA04	Phase 3	[3]
Gallopamil	DMXBR27	Asthma	CA23	Phase 2	[4]
SLV 306	DMCDON3	Acute decompensated heart failure	BD1Z	Phase 2	[5]
SLV-334	DMXCJKY	Brain injury	NA07.Z	Phase 2	[6]
VX-15	DMLWM4G	Huntington disease	8A01.10	Phase 2	[7]
Sampatrilat	DMXTOVE	Hypotension	BA20-BA21	Phase 2	[8]
SLV-338	DM7WKTM	Cardiovascular disease	BA00-BE2Z	Phase 1	[9]
GW-796406	DMQ46DN	Hypotension	BA20-BA21	Phase 1	[4]
Debio 0827	DMQIEFB	Chronic pain	MG30	Phase 1	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Neutral endopeptidase (MME)	TT5TKPM	NEP_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Potent non-peptidic dual inhibitors of endothelin-converting enzyme and neutral endopeptidase 24.11, Bioorg. Med. Chem. Lett. 7(8):1059-1064 (1997).
2	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
3	Neutral endopeptidase inhibitor suppresses the early phase of atrial electrical remodeling in a canine rapid atrial pacing model. Indian Pacing Electrophysiol J. 2008 Apr 1;8(2):102-13.
4	Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13.
5	The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13-14):743-8.
6	Clinical trials in traumatic brain injury: past experience and current developments.Neurotherapeutics.2010 Jan;7(1):115-26.
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8	Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens. 1999 Jun;12(6):563-71.
9	Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage. Clin Lab. 2011;57(7-8):507-15.
10	Clinical pipeline report, company report or official report of Debiopharm (2011).